Drug Trial Radar · NCT04626947
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Last checked: Nov 20, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
19
Actual
Start
Oct 14, 2021
Primary completion
Apr 24, 2024
Study completion May 31, 2024
Sponsor
- Lead sponsor
- David Binion, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Nov 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
Conditions
- Inflammatory Bowel Diseases
- Ulcerative Colitis
- Crohn Disease
- C. Diff. Infections
Interventions
BezlotoxumabBiological
Bezlotoxumab infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Recurrent C. Diff Infection at 90 DaysTime frame: 90 days
- Number of Participants With Recurrent C. Diff Infection at 12 MonthsTime frame: 12 months
- Number of Participants With Recurrent C. Diff Infection at 24 MonthsTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.